NCT06773936 2026-03-04
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Enrolling by invitation
Clinical Trials
9 trialsNCT06723015 2025-11-18
Tau PET Outcomes With Anti-amyloid Immunotherapies
Mayo Clinic
Phase 2 Enrolling by invitation
NCT06544798 2025-10-16
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
MeiraGTx UK II Ltd
Phase 2 Enrolling by invitation
NCT03628612 2025-08-07
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Autolus Limited
Phase 2 Enrolling by invitation
NCT06054178 2025-07-28
Identification of Nerves Using Fluorescein Sodium
Stanford University
Phase 2 Enrolling by invitation
NCT02646839 2025-05-04
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
Pediatric Transplantation & Cellular Therapy Consortium
Phase 2 Enrolling by invitation
NCT06931613 2025-04-17
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
St. Petersburg State Pavlov Medical University
Phase 2 Enrolling by invitation
NCT06560879 2025-03-14
Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children with Leukemia
National Institute of Pediatrics, Mexico
Phase 2 Enrolling by invitation
NCT05396118 2024-05-14
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Rigshospitalet, Denmark
Phase 2 Enrolling by invitation